Distributed Manufacturing, Foreign Establishments, and Why the FDA's New Proposed Rule Matters to Clinical Pharmacology

Clinical Pharmacology in Drug Development · Published 2026-08-01 · DOI 10.1002/cpdd.70088

Free full text

Authors (1)

Amalia M. Issa

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

Issa, A. (2026). Distributed Manufacturing, Foreign Establishments, and Why the FDA's New Proposed Rule Matters to Clinical Pharmacology. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.70088

Related articles